Recombinant antibody binding to partially carboxylated osteocalcin with Glu at position 17
| Inventor | Institute |
|---|---|
| Kaisa Ivaska-Papaioannou ; Urpo Lamminmäki | University of Turku |
| Cat. #: | 157722 |
|---|---|
| Tool sub type: | Primary antibody |
| Unit size: | 100 ug |
| Research Fields: | Disease (not cancer);Metabolism |
| Application: | IF ; Fn |
| Target: | osteocalcin – partially carboxylated with Glu at position 17 |
| Reactivity: | Human |
| Host: | Human |
| Class: | Recombinant |
| Alternate name: | Uncarboxylated osteocalcin, uc-Osteocalcin, uc-OC, bone gamma-carboxyglutamic acid-containing protein, BGLAP |
|---|---|
| Product description: | Recombinant antibody binding to partially carboxylated osteocalcin with Glu at position 17 |
| Conjugation: | Unconjugated |
| Isotype: | IgG1 kappa |
| Immunogen: | Human full-length ucOC peptide (149, Glu at positions 17, 21 and 24; C23C29 bridge) |
| Target background: | Recombinant antibody binding to partially carboxylated osteocalcin with Glu at position 17 |
|---|
| Format: | Liquid |
|---|---|
| Shipping conditions: | Dry ice |
| References: |
Arponen et al. 2020. Calcif Tissue Int. 107(6):529-542. PMID: 32839842. |
|---|
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151029 | Anti-HSVICP8 [11E2] |
Key Info
Anti-HSVICP8 [11E2]
|
View Tool | |||||||||||||||||||
| 151031 | Anti-RuvA [RuvA 12C6] |
Key Info
Anti-RuvA [RuvA 12C6]
|
View Tool | |||||||||||||||||||
| 151033 | Anti-HSVUL42 [13C9] |
Key Info
Anti-HSVUL42 [13C9]
|
View Tool | |||||||||||||||||||
| 151034 | Anti-HSVUL42 [13D11] |
Key Info
Anti-HSVUL42 [13D11]
|
View Tool | |||||||||||||||||||
| 151038 | Anti-Cytochrome P450 4A2, 4A3 [Clo4] |
Key Info
Anti-Cytochrome P450 4A2, 4A3 [Clo4]
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.